Bank of New York Mellon
EIKN

Bank of New York Mellon’s Eikon Therapeutics EIKN Stock Holding History

Bank of New York Mellon’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
+47,788
New +$488K ﹤0.01% 3641

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.2B AUM 41.24% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bank of New York Mellon's EIKN Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Eikon Therapeutics (EIKN) in Q2 2026: 47,788 shares worth $624K. The stake represents ﹤0.01% of the portfolio and ranks #3641 among its holdings.

29 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • Bank of New York Mellon held 47,788 shares of Eikon Therapeutics worth $624K as of Q2 2026.
  • Eikon Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • Eikon Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3641 holding.
  • 29 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.